The Ethics of Hormone Therapy: When Guidelines Meet Individual Lives
Written and edited by Sarah Bonza MD, MPH, FAAFP, MSCP, DipABLM, NBC-HWC
Current evidence supports hormone therapy as safe and effective for appropriately selected women, particularly when started before age 60 or within 10 years of menopause.
A woman sits across from you—articulate, well-read, and clear about what she wants. She’s done her homework. She’s aware of the risks, understands the data, and still asks for hormone therapy. You pause—not because you want to deny her, but because you’ve been conditioned to.
You recall the guidelines. You remember the lawsuits. You remember the headlines that turned an entire generation of women away from treatment. And yet—there she is, asking you to listen.
This is where medicine gets complicated—where evidence-based practice meets patient autonomy, and where our duty to “do no harm” collides with our responsibility to honor informed choice.
The Shadow of WHI: How Fear Became Policy
The 2002 Women’s Health Initiative (WHI) study didn’t just shift prescribing—it reshaped the cultural and clinical landscape of menopause care.[1-2] Overnight, hormone therapy became synonymous with breast cancer risk. Millions of women discontinued therapy, and many clinicians learned to say “no” reflexively.
But the nuance was lost in translation.
The WHI evaluated conjugated equine estrogens and synthetic progestins—not bioidentical hormones. The average participant was 63 years old, well beyond the optimal window for initiation. The absolute risk increase was small—roughly eight additional breast cancers per 10,000 women per year—and the same study showed reductions in fractures, colon cancer, and diabetes. Later analysis yielded the timing hypothesis: hormone therapy started within 10 years of menopause may actually confer cardiovascular protection.
Yet the damage was done. Fear replaced discussion, and caution became policy. An entire generation of women suffered—not because of data, but because of its misinterpretation.
Following the results of the 2002 Women’s Health Initiative study, an entire generation of women suffered from menopause symptoms. Not because of data, but because of its misinterpretation.
The Ethical Framework: Four Principles in Tension
Every decision in clinical medicine rests on four ethical pillars—autonomy, beneficence, non-maleficence, and justice. In menopause care, these principles often pull us in opposite directions.[3]
Autonomy reminds us that an informed, competent patient has the right to accept risks we might not choose for them.
Beneficence asks whether denying treatment that could restore vitality truly serves her best interests.
Non-maleficence cautions us to “do no harm”—but does harm mean a possible increased risk decades from now, or the certain suffering from unrelieved symptoms today?
Justice demands consistency. We readily prescribe NSAIDs with GI risks, statins with myalgias, and oral contraceptives with thrombotic potential. Why, then, do we hold menopausal hormone therapy to a higher moral and legal standard?
The Legal Reality: Informed Consent Is Your Protection
Fear of litigation often drives clinical conservatism. But avoidance isn’t protection—documentation is. The legal question isn’t whether you prescribed hormones; it’s whether you obtained informed consent.[4]
That means:
Transparent disclosure of risks, benefits, and alternatives.
Demonstrated patient comprehension—not just a signature.
Voluntary decision-making without coercion.
Thorough documentation of the discussion.
Courts favor shared decision-making, not blanket refusal. Liability arises when we fail to inform, overrule autonomy without justification, or deviate from standards without explanation.
In complex cases, meticulous documentation and shared decision-making aren’t just best practice—they’re ethical and legally sound medicine.
Hormone therapy can improve symptoms for women with significant vasomotor symptoms.
The Data We Actually Have
Current evidence supports hormone therapy as safe and effective for appropriately selected women, particularly when started before age 60 or within 10 years of menopause.
Low-risk scenarios:
Significant vasomotor symptoms impacting quality of life
Bioidentical transdermal estradiol with micronized progesterone
Lowest effective dose
Higher-risk scenarios (requiring careful discussion):
Prior breast cancer or LCIS
History of thromboembolism or stroke
Known thrombophilia
Active liver disease
Unexplained vaginal bleeding
“High risk” doesn’t mean “never.” It means more conversation, more caution, more collaboration.[6-7]
Current evidence supports hormone therapy as safe and effective for appropriately selected women, particularly when started before age 60 or within 10 years of menopause.
The Ethics of Individualized Care
Ethical prescribing of hormone therapy in modern practice demands both science and empathy.
Start with the science, not the fear. Know the data, differentiate absolute from relative risk, and present numbers accurately.
Assess the whole person. Evaluate not just her medical history, but her quality of life, goals, and risk tolerance.
Layer your risk mitigation. Favor bioidentical over synthetic formulations, transdermal over oral delivery, and progesterone over progestins where applicable.
Document extensively. Chart risk discussions, patient understanding, and the collaborative reasoning behind your plan.
Create partnership, not paternalism. Educate without dictating. A well-informed woman deserves both your honesty and your trust.
The Question Every Clinician Should Ask
When faced with a complex case, pause and ask:
Am I saying no because it’s truly contraindicated—or because I’m afraid?
Am I protecting the patient—or protecting myself?
If she were my own sister, with these same symptoms, what would I want her doctor to do?
Guidelines are meant to guide, not govern. They describe populations, not individuals. The woman in front of you isn’t a statistic—she’s a person capable of sharing responsibility for risk.
Modern menopause care demands nuance. It requires courage to balance science, safety, and humanity in the same conversation.
Moving Forward: A Call for Thoughtful Practice
We can hold multiple truths at once:
Hormone therapy carries real risks.
Those risks have often been overstated.
Many women have suffered unnecessarily from fear-based medicine.
Informed adults can accept reasonable risk for meaningful benefit.
Shared decision-making protects both patient and physician.
As clinicians, we must update our understanding beyond 2002. Challenge the reflexive “no.” Lead with evidence, not apprehension. Document with diligence. Practice with empathy.
And above all—trust informed women to know what matters most to them.
Modern menopause care demands nuance. It requires courage to balance science, safety, and humanity in the same conversation. The most ethical choice isn’t always the most conservative one. Sometimes, our greatest harm is in withholding treatment, not in providing it.
That is what true evidence-based, patient-centered care looks like.
References
[1] P. Stute, J. Marsden, N. Salih, and A. Cagnacci, “Reappraising 21 years of the WHI study: Putting the findings in context for clinical practice,” Maturitas, vol. 174. Elsevier BV, p. 8, May 11, 2023. https://doi.org/10.1016/j.maturitas.2023.04.271
[2] S. L. Crawford et al., “Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study Results,” Menopause The Journal of The North American Menopause Society, vol. 26, no. 6, p. 588, Dec. 2018, https://doi.org/10.1097/gme.0000000000001282
[3] C. C. C. Mendoza, L. A. Robledo, G. L. Martínez, C. A. J. Zamarripa, and M. E. Hernández-Caballero, “Ethical Considerations in Research and Medical Care of Menopause,” in InTech eBooks, 2018. https://doi.org/10.5772/INTECHOPEN.74666
[4] V. G. Koch, “Reimagining Informed Consent: From Disclosure to Comprehension,” SSRN Electronic Journal, Jan. 2023, https://dx.doi.org/10.2139/ssrn.4346436
[5] C. A. Stuenkel et al., “Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 11, p. 3975, Oct. 2015, https://doi.org/10.1210/jc.2015-2236
[6] K. Magraith and C. Jang, “Management of menopause,” Australian Prescriber, vol. 46, no. 3. NPS MedicineWise, p. 48, Oct. 22, 2023. https://doi.org/10.18773/austprescr.2023.014
[7] S. Middeldorp et al., “American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing,” Blood Advances, vol. 7, no. 22, p. 7101, May 2023, https://doi.org/10.1182/bloodadvances.2023010177